Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer

Show full item record



Permalink

http://hdl.handle.net/10138/335887

Citation

Khatun , M , Urpilainen , E , Ahtikoski , A , Arffman , R K , Pasanen , A , Puistola , U , Tapanainen , J S , Andersson , L C , Butzow , R , Loukovaara , M & Piltonen , T T 2021 , ' Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer ' , Pathology and Oncology Research , vol. 27 , 1609936 . https://doi.org/10.3389/pore.2021.1609936

Title: Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer
Author: Khatun, Masuma; Urpilainen, Elina; Ahtikoski, Anne; Arffman, Riikka K.; Pasanen, Annukka; Puistola, Ulla; Tapanainen, Juha S.; Andersson, Leif C.; Butzow, Ralf; Loukovaara, Mikko; Piltonen, Terhi T.
Contributor: University of Helsinki, Department of Pathology
University of Helsinki, HUS Gynecology and Obstetrics
University of Helsinki, Medicum
University of Helsinki, Department of Pathology
University of Helsinki, Helsinki University Hospital Area
Date: 2021-09-28
Language: eng
Number of pages: 9
Belongs to series: Pathology and Oncology Research
ISSN: 1219-4956
URI: http://hdl.handle.net/10138/335887
Abstract: Stanniocalcin-1 (STC-1) is a glycoprotein hormone involved in diverse biological processes, including regulation of calcium phosphate homeostasis, cell proliferation, apoptosis, inflammation, oxidative stress responses, and cancer development. The role of STC-1 in endometrial cancer (EC) is yet to be elucidated. In this study, we investigated the protein expression pattern of STC-1 in a tissue microarray (TMA) cohort of hysterectomy specimens from 832 patients with EC. We then evaluated the prognostic value of STC-1 expression regarding the clinicopathologic features and patients survival over a period of 140 months. Our results revealed that in EC tissue samples, STC-1 is mainly localized in the endometrial epithelium, although some expression was also observed in the stroma. Decreased STC-1 expression was associated with factors relating to a worse prognosis, such as grade 3 endometrioid tumors (p = 0.030), deep myometrial invasion (p = 0.003), lymphovascular space invasion (p = 0.050), and large tumor size (p = 0.001). Moreover, STC-1 expression was decreased in tumors obtained from obese women (p = 0.014) and in women with diabetes mellitus type 2 (DMT2; p = 0.001). Interestingly, the data also showed an association between DNA mismatch repair (MMR) deficiency and weak STC-1 expression, specifically in the endometrial epithelium (p = 0.048). No association was observed between STC-1 expression and disease-specific survival. As STC-1 expression was particularly low in cases with obesity and DMT2 in the TMA cohort, we also evaluated the correlation between metformin use and STC-1 expression in an additional EC cohort that only included women with DMT2 (n = 111). The analysis showed no difference in STC-1 expression in either the epithelium or the stroma in women undergoing metformin therapy compared to metformin non-users. Overall, our data may suggest a favorable role for STC-1 in EC behavior; however, further studies are required to elucidate the detailed mechanism and possible applications to cancer treatment.
Subject: 3111 Biomedicine
disease-specific survival
endometrioid carcinoma
metformin
stanniocalcin-1
type 2 diabetes mellitus
uterine cancer
METFORMIN
CELLS
BIOMARKER
RENAL ISCHEMIA/REPERFUSION INJURY
INVASION
ELEVATED EXPRESSION
GENE-EXPRESSION
CARCINOMA
3123 Gynaecology and paediatrics
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
pore_27_1609936.pdf 1.493Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record